Sheldon H. Preskorn, M.D. Curriculum Vitae

ABBREVIATED CURRICULUM VITAE
07-23-03
View Acrobat formatted file (361KB)

NAME: Sheldon Harrison Preskorn, M.D.
CITIZENSHIP: United States of America
MEDICAL SCHOOL: University of Kansas, Kansas City, Kansas (M.D., 1974)
WEBSITE: www.preskorn.com

POSTGRADUATE:

Pathology Residency, University of Kansas Medical Center (UKMC) Kansas City, Kansas, 1973-75
Rotating Internship, Internal Medicine/Psychiatry UKMC, Kansas City, Kansas, 1975-76
Psychiatry Residency, Washington University School of Medicine, St. Louis, Missouri, 1976-78

ACADEMIC APPOINTMENTS:

Professor and Chairman, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine (UKSM), Wichita, Kansas, 1999-
Professor and Vice Chairman, Department of Psychiatry, UKSM, Wichita, Kansas, 1985-99
Professor of Psychiatry and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, 1984-85
Associate Professor of Psychiatry and Pharmacology Toxicology and Therapeutics, UKSM, Kansas City, Kansas, 1981-84
Assistant Professor of Psychiatry and Pharmacology Toxicology and Therapeutics, UKSM, Kansas City, Kansas, 1978-81
Assistant Instructor in Psychiatry, Washington University School of Medicine, St. Louis, Missouri, 1976-78

DIRECTORSHIP POSITIONS:

Medical Director, Clinic Research Unit, 1990-
President and Medical Director, Psychiatric Research Institute, 1987- Via Christi Regional Medical Center, Wichita, Kansas
Director, Outpatient Clinic Department of Psychiatry, UKSM, Wichita, Kansas, 1991-99
Chief, Psychiatry Service, Wichita Veterans Administration Medical Center, Wichita, Kansas, 1985-91

LICENSURE:

Permanent Kansas Medical License # 4-6344
Permanent Missouri Medical License # 00101337

CONSULTANTSHIP:

Menninger Foundation, Topeka, Kansas, 1992-98.

AWARDS:

Foxington Who's Who Directory of Executives and Professionals, 2000
National Registry of Who's Who, Life Member, 2000
The Best Doctors in America, 4th Edition, 1998
American Psychiatric Association, Nancy C.A. Roeske, M.D., Certificate of Excellence in Medical Student Education, 1998
National Alliance for the Mentally Ill, Exemplary Psychiatrist Award, 1993
The Mental Health Association in Kansas, 1989
Alliance for Mentally Ill in Sedgwick County, 1988
Research Scientist Development Award (NIMH), 1980-1985
American Academy of Clinical Psychiatry, Clinical Research Award, 1984
University of Kansas College of Health Sciences Research Award, 1983
American Academy of Clinical Psychiatry Annual Research Award, 1982
A.E. Bennett Neuropsychiatric Research Foundation Award, 1978
Roche Laboratory Award for Neuroscience, 1978
Mead-Johnson Award for Overall Excellence in Research, 1978
Walter C. Menninger Neuropsychiatry Award, 1978
Outstanding Young Men of America, 1977 and 1982
KUMC Psychiatric Housestaff Research Award, 1976
KUMC Pathology Housestaff Research Award, 1975
Chester M. Goodwin Award for Neurological Research, 1971
Who's Who in American Colleges and Universities, 1969

FELLOWSHIPS:

Maurice Falk Fellowship, 1975-78
University of Kansas Research Fellowship, 1971
Wichita State University Research Assistantship, 1970
Wichita State University Honors Fellowship, 1969-70

CERTIFICATION:

Psychiatry plus Geriatric qualifications, American Board of Psychiatry and Neurology, 1997
Diplomate, American Board of Psychiatry and Neurology, 1981
Diplomate, National Board of Medical Examiners, 1975

EDITORIAL BOARDS:

Associate Editor, Journal of Clinical Psychiatry, 2001
Associate Editor, Journal of Clinical Psychopharmacology, 2000
Contributing Editor, Journal of Psychiatric Practice, (formerly JPPBH) 2000 -
Contributing Editor, Journal of Practical Psychiatry and Behavioral Health, 1995-99
American Hospital Formulary Service Drug Information, 1998
Associate Editor, Journal of Clinical Psychiatry, 1978-88
Associate Editor, Current Psychiatry, 2003

MAJOR RESEARCH INTEREST:

Psychopharmacology, affective and anxiety disorders, neuroscience.

REVIEWER FOR SCIENCE:

American Hospital Formulary Service Drug Information Monographs
American Journal of Geriatric Psychiatry
American Journal of Primatology
American Journal of Psychiatry
American Society of Pharmacology and Experimental Therapeutics
Annals of Pharmacotherapy
Archives of General Psychiatry
Biological Psychiatry
Bipolar Disorders
Canadian Psychiatric Research Foundation
Clinical Pharmacokinetics
CNS Drugs
Currents in Affective Illness
Depression and Anxiety
Drug and Aging Journal
Drugs
European Journal of Pharmacology
General Hospital Psychiatry
Geriatric Agitation Guidelines
Geriatric Psychiatry
International Journal of Neuropsychopharmacology
International Journal of Neuropsychiatry
International Journal of Psychiatry in Medicine
Journal of Affective Disorders
Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology
Journal of Neuropsychiatry and Clinical Neurosciences
Journal of Pharmaceutical Sciences
Journal of Pharmacy Technology
Journal of Practical Psychiatry and Behavioral Health
Journal of Psychopharmacology
Journal of the American Medical Association
Life Sciences
Neuropsychopharmacology
Pharmacoeconomics
Psychiatric Times
Psychometics
Psychopharmacology
Therapeutics Bulletin

REVIEW COMMITTEES:

Panel Member, Center for Scientific Review, NIMH Special Emphasis Panel, 1999-
Panel Member, Center for Scientific Review, NIH Study Sect.-Genetic Sciences, 1999
Member, International Advisory Board for the Guidelines in Depression, 1998-2000
Member, Via Christi Regional Medical Center Institutional Review Board, 1989-
Moderator-Faculty, AMERICAN PSYCHIATRIC ASSOCIATION Physician Awareness Program, 1987-89
Reviewer (Member), Wesley Foundation Scientific Advisory Panel, 1987-1989
Reviewer (ad hoc), VA Merit Rev. Mental Health and Behavioral Science Comm., 1985
Reviewer (ad hoc), Nat'l Inst. Neurological and Communicative DOs and Stroke (NINCDS) study section on Spinal Cord Trauma Centers, 1983 and 1987
Reviewer (ad hoc) National Science Foundation Neuropharmacology Section, 1983-87
Reviewer (ad hoc), NIMH Psychopharmacological, Biological, and Physical Treatments Research Review Committee (TDA2), 1986
Member, FDA Psychopharmacologic Drugs Advisory Committee, 1982-86
Reviewer (ad hoc), NIMH Mental Health Behavioral Science Research Review, 1984

SOCIETIES:

International Society for Affective Disorders, 2001-02
American Psychopathological Association, Fellow, 1989
American Psychiatric Association, Member, 1979; Fellow, 1987, Distinguished Fellow, 2003
Society of Neuroscience, Member 1978; Local Chapter Secretary/Treasurer 1980; President 1981-82
American Society of Clinical Pharmacology and Therapeutics, Member, 1979
Society of Biological Psychiatry, Member, 1978
Alpha Omega Alpha, Member, 1973
American Medical Association, Member, 1971
Phi Kappa Phi, Member, 1970
Omicron Delta Kappa, President, 1969
Wichita State University Honors Society, Member, 1969

GRANTS: Continuous funding since 1978. Supplemental report available.

ORGANIZATIONAL OFFICES:

Member, Sedgwick County Task Force on Suicide Prevention, 2001-
Scientific Advisor, MHA of So. Central Kansas, 2001-
NIMH Outreach and Education, 2000-
Sedgwick County Alliance for Mentally Ill, 1996-
Advisory Committee, Kansas Alliance for the Mentally Ill, 1993-
Member, University of Kansas School of Medicine Research Committee, 1992-94
Member, Board of Directors, Project Awareness for Major Mental Illness, 1990-
Founding President, Project Awareness for Major Mental Illness, 1990-
Member, Scientific Program Committee for American Society of Clinical Pharmacology and Therapeutics, 1983-85
Chairman, KUMC Faculty and Student Affairs Committee, 1983-84
Member, Governor's Advisory Commission on Mental Health and Retardation Services and Community Mental Health Programs, State of Kansas, 1979-84
Member, American Psychiatric Association Program Committee (National), 1978-82
Chairman, Subcommittee on New Research, 1980-82
Member, American Psychiatric Association Council - Research and Development, 1976 -78
Member, American Psychiatric Association Task Force Tardive Dyskinesia, 1976-79
Member, Continuing Education Committee for Kansas Psychiatric Society, 1980-82
Member, KUMC Human Studies Research Committee, 1979-84
Member, KUMC Peer Utilization Review Committee, 1978-80
Representative, KUMC Housestaff Association, 1976
Representative, Association of American Medical Colleges, 1971-73
Treasurer, KUMC Chapter (student) of the Kansas Medical Society, 1970-71
President/Administrative/Executive Coordinator, WSU Student Union Activities Board, 1969-70
Educational/Cultural Coordinator, WSU Student Union Activities Board, 1968-69
Chairman, Wichita Film Society, 1967-68

VISITING PROFESSOR/LECTURER:

Presented at meetings and/or universities in the following locations on one or more occasions:

	INTERNATIONAL LOCATIONS
	Brisbane, Australia Melbourne, Australia Sydney, Australia Tasmania, Australia Vienna, Austria Brussels, Belgium Hamilton, Bermuda Rio de Janeiro, Brazil Halifax, Canada Hamilton, Canada London, Canada Montreal, Canada Toronto, Canada Saskatchewan, Canada Vancouver, Canada Winnipeg, Canada Bejing, China Hong Kong, China Shanghai, China Copenhagen, Denmark Odense, Denmark Alexandria, Egypt Cairo, Egypt London, England Cannes, France Nice, France Paris, France Berlin, Germany Dresden, Germany Frankfurt, Germany Giessen, Germany Hamburg, Germany Hannover, Germany Marburg, Germany Muenster, Germany Tuebingen, Germany	Athens, Greece Rhodes, Greece Budapest, Hungary Jerusalem, Israel Cagliari, Italy Florence, Italy Palermo, Italy Brazil Rome, Italy Venice, Italy Kyoto, Japan Seoul, Korea Mexico City, Mexico Acapulco, Mexico Monte Carlo, Monaco Amsterdam, Netherlands Auckland, New Zealand Oslo, Norway Trondheim, Norway Tromso, Norway Las Croabas, Puerto Rico San Juan, Puerto Rico Glascow, Scotland Capetown, South Africa Johannesburg, South Africa Badojoz, Spain Barcelona, Spain Madrid, Spain Linkoping, Sweden Lund, Sweden Stockholm, Sweden Basel, Switzerland Berne, Switzerland Geneva, Switzerland Lausanne, Switzerland Zurich, Switzerland

	UNITED STATES OF AMERICA
	University of Alabama-Birmingham University of Southern Alabama University of Arkansas University of Arizona Loma Linda University Stanford University University of California-Davis University of California-Irvine University of California-LA University of California-Sacramento University of California-San Fransisco University of Southern California University of Connecticut-Institute Living Yale University George Washington University Howard University University of Miami University of South Florida University of Hawaii Chicago University Loyola University Northwestern University Purdue University Rush Presbyterian University Southern Illinois University Menninger Foundation Wichita State University Boston University Harvard University-Beth Israel Hospital Harvard University-Mass. Mental Health Center Harvard University-McLean Hospital Massachusetts General Hospital Tufts University John Hopkins University Henry Ford Hospital-Detroit University of Michigan Wayne State University Mayo Clinic University of Minnesota St. Louis University University of Missouri-Columbia Washington University	University of Missouri-Kansas City Tulane University University of Mississippi Duke University East Carolina University Vanderbilt University University of North Dakota Creighton University University of Nebraska University of New Jersey Dental University of Nevada Columbia University Cornell University New York University State University of New York-Albany State University of New York-Buffalo State University of New York-Stony Brook Case Western Reserve University, OH Cleveland Clinic Medical College of Ohio Ohio State University University of Ohio Oklahoma Department of Mental Health University of Oklahoma University of Oregon Thomas Jefferson University University of Pennsylvania University of Pittsburg Bowman-Grey University Medical College of South Carolina University of South Carolina-Columbia University of South Dakota University of Tennessee Southwestern Medical College-Dallas University of Texas-Galveston University of Texas-San Antonio University of Utah University of Virginia University of Vermont University of Wisconsin University of Wisconsin Medical College University of Wisconsin-Madison University of Wisconsin-Milwaukee

SUMMARIZED PUBLICATIONS:

Total publications include over 200 journal articles, 40 book chapters and 7 books. Principal topics have been psychopharmacology, affective and anxiety disorders and neuroscience.

ITEMIZED PUBLICATIONS: (abbreviated CV only contains publications since 1997)

JOURNAL ARTICLES:

Preskorn SH, Selection of an antidepressant: mirtazapine. J Clin Psychiatry. 1997;58(suppl 6):3-8
Preskorn S, Foreward. Journal of Clinical Pharmacokinetics 32(suppl 1):0, 1997
Preskorn SH, Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32:1-21
Tremaine L, Wilner K, Preskorn S, A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Journal of Clinical Pharmacokinetics 32(suppl 1):31-36, 1997
Gardner M, Baris B, Wilner K, Preskorn S, Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Journal of Clinical Pharmacokinetics 32(suppl 1):43-49, 1997
Preskorn SH, Alderman J, Greenblatt DJ, Horst WD, Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacology Bulletin 33(4):659-665, 1997
Alderman J, Preskorn S, Greenblatt D, et al, Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91
Preskorn SH, Pharmacotherapeutic profile of venlafaxine. Euoropean Psychiatry 12(S4):285-294, 1997
Preskorn SH, Harvey A, Stanga C, Drug interactions and their role in patient care. Curr Rev Mood Anxiety Disord. 1997;1: 203-214
Bhatara VS, Magnus RD, Paul KL, Preskorn SH, Serotonin syndrome induced by venlafaxine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. The Annals of Pharmacotherapy 32(4):432-436, 1998
Preskorn SH, Catterson M, Antidepressants and the elderly: Focus on newer agents. International Journal of Geriatric Psychopharmacology 1:66-77, 1998
Preskorn SH, Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol. 1998;12:S89-S97
Horst WD, Preskorn SH, Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. Journal of Affective Disorders 51:237-254, 1998
Horst WD, Preskorn SH, The pharmacology and mode of action of venlafaxine. Review of Contemporary Pharmacotherapy 9:293-302, 1998
Preskorn SH, Antidepressant options in primary care. Clinical Cornerstone 1(4):31-55, 1999
Burke MJ, Preskorn SH, Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. Clinical Pharmacokinetics 1999;37:147-65
Catterson M, Martin RL, Preskorn SH, Psychopharmacologic drug-drug interactions in the elderly. Clinical Geriatrics 7(9):46-54, 1999
Harvey AT, Rudolph RL, Preskorn SH, Evidence of the dual mechanisms of action of venlafaxine in healthy male volunteers. Archives of General Psychiatry 57(5)503-509, 2000
Shad MU, Marsh C, Preskorn SH, The economic consequences of a drug-drug interaction. Journal of Clinical Psychopharmacology 21(1):119-20, 2001
Findling RL, Marcus RN, D’Amico F, Reed MD, Preskorn SH, Magnus RD, Marathe P, Nefazodone pharmacokinetics in depressed children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 39(8):1008-1016, 2000
Harvey AT, Preskorn SH, Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001;21:161-6
Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M, Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. Journal of Clinical Psychiatry 62(6):413-420, 2001
Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D, Ghosh K, Ball W, Reines S, and SPA Depression Study Group, Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. Clinical Neuropharmacology Submitted Sep 15, 2002
Werder SF, Preskorn SH, Managing polypharmacy walking the fine line. Current Psychiatry Submitted Jan 1, 2002

COLUMNS:

Preskorn SH, Let the data speak to you. J Pract Psychiatry Behav Health 1997;3(1):45-8
Preskorn SH, Do you believe in magic? J Pract Psychiatry Behav Health 1997;3:99-103
Preskorn SH, Patients don’t fail treatments, treatments fail patients. J Pract Psychiatry Behav Health 1997;3:165-8
Preskorn SH, The appearance of knowledge. J Prac Psych Behav Hlth. 1997;3:233-238
Preskorn SH, I don’t see ’em. J Prac Psych Behav Hlth. 1997; 3:302-307
Preskorn SH, Pandora’s Box: Pregnancy and antidepressants. Journal of Practical Psychiatry and Behavioral Health 3(6):363-365, 1997
Preskorn SH, Do you feel lucky? J Prac Psycho Behav Hlth. 1998;4:37-40
Preskorn SH, Marooned: Only one choice. J Prac Psych and Behav Hlth 1998;4:110-4
Preskorn SH, Baird S, 11.2 billion dollars: Is it worth it?. J Pract Psychiatry Behav Health 1998;4:163-8
Preskorn SH, A message from Titanic. J Prac Psych Behav Hlth. 1998;4:236-242
Preskorn SH, Sweetness!. J Prac Psych and Behav Hlth 1998;4:304-8
Preskorn SH, What happened to Tommy? J Pract Psychiatry Behav Health 1996;1:39-43
Preskorn SH, The slippery slide. J Pract Psychiatry Behav Health 1999;5:50-5
Preskorn SH, Finding the signal through the noise: The use of surrogate markers. J Pract Psychiatry Behav Health 1999;5:104-109
Preskorn SH, A tale of two patients. J Pract Psychiatry Behav Health 1999;5:160-164
Preskorn SH, Defining "Is." J Pract Psychiatry Behav Health 1999;5:224-8
Preskorn SH, De-spinning in vitro data. J Pract Psychiatry Behav Health 1999;5:283-7
Preskorn SH, Two in one: The venlafaxine story. J Pract Psychiatry Behav Health 1999;5:346-50
Preskorn SH, Bupropion: What mechanism of action? Journal of Psychiatric Practice 2000;6:39-44
Preskorn SH, Imipramine, Mirtazapine, and Nefazodone: Multiple targets. Journal of Psychiatric Practice 2000;6:97-102
Preskorn SH, The adverse effect profiles of the selective serotonin reuptake inhibitors: Relationship to in vitro pharmacology. Journal of Psychiatric Practice 2000;6:153-7
Preskorn SH, The relative adverse effect profile of non-SSRI antidepressants: Relationship to in vitro pharmacology. Journal of Psychiatric Practice 2000;6:218-23
Preskorn SH, The human genome project and modern drug development in psychiatry. Journal of Psychiatric Practice 2000;6:272-276
Preskorn SH, The stages of drug development and the human genome project: Drug discovery. Journal of Psychiatric Practice 2000;6:341-4
Preskorn SH, Silkey B, Multiple medications, multiple considerations. Journal of Psychiatric Practice 2001;7:48-52
Preskorn SH, The human genome project and drug discovery in psychiatry: Identifying novel targets. Journal of Psychiatric Practice 2001;7:133-7
Preskorn SH, Antipsychotic drug development in the pre-human genome era: A full circle. Journal of Psychiatric Practice 2001;7:209-213
Preskorn SH, Drug discovery in psychiatry: Drilling down on the target of interest. Journal of Psychiatric Practice 2001;7:267-72
Preskorn SH, Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. Journal of Psychiatric Practice 2001;7:336-40
Preskorn SH, Drug development in psychiatry and genomics: From E. coli to man. Journal of Psychiatric Practice 2001;7:415-9
Preskorn SH, Drug approvals and withdrawals over the last 60 years. Journal of Psychiatric Practice 2002;7:410
Preskorn SH, Silkey B, Jones T, Physician perceptions of drug-drug interactions and how to avoid them. Journal of Psychiatric Practice 8(2):112-115, March 2002
Preskorn SH, Baker B, The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development, and the human genome project. Journal of Psychiatric Practice 8(3):170-177, May 2002
Preskorn SH, Fatal drug-drug interaction as a differential consideration in apparent suicides. Journal of Psychiatric Practice 2002;8:233-8
Preskorn SH, Clinical pharmacology case conference: A suicide attempt? Journal of Psychiatric Practice 2002;8:306-10
Preskorn SH, Polypharmacy in a patient with refractory major depression: Part I. The case. Journal of Psychiatric Practice 2002;8:370-6
Preskorn SH, Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. Journal of Psychiatric Practice 9(1), January 2003
Preskorn SH, Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I) Journal of Psychiatric Practice 9(2), March 2003
Preskorn SH, Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II) Journal of Psychiatric Practice 2003;9:228-36
Preskorn SH, Relating clinical trials to psychiatric practice: Part I: the case of a 13-year old on aripiprazole and fluoxetine. Journal of Psychiatric Practice 9(4), July 2003

BOOK CHAPTERS:

Stanga C, Preskorn SH, Use of the laboratory in psychiatry. In: Current Psychiatric Therapy II (ed) Dunner DL., W.B. Saunders Company, Phildelphia, Chapter 7, pp 59-74, 1997
Horst WD, Preskorn SH, Intracellular and intercellular principles of the pharmacotherapy of patients with neuropsychiatric disorders. In: American Psychiatric Press Textbook of Neuropsychiatry, 3rd Edition. American Psychiatric Press Inc., Washington DC. Chapter 3, pp 55-75, 1997
Knesper DJ, Riba MB, Schwenk TL, Primary Care Psychiatry. Philadelphia, Pa: WB Saunders Co; 1997
Catterson ML, Preskorn SH, Martin RL, Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatric Clinics of North America. 20(1):205-218, 1997
Preskorn SH, Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, eds. European Cooperation in the Field of Scientific and Technical Research. Belguim: European Commission; 1998:45-61
Preskorn SH, Harvey A, Cytochrome P450 enzymes and psychopharmacology. In: Watson S, ed. Psychopharmacology: The fourth generation of progress [CD ROM version]. Philadelphia: Raven; in press
Shad MU, Preskorn SH, Antidepressants. In: Levy R, Thummel KE, Trager W, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions - Drugs as Inhibitors of Metabolic Enzymes Treatment of CNS Diseases. Philadelphia, Pa: Lippincott, Williams & Wilkins. In press
Preskorn SH, Catterson ML, Pharmacokinetics of Antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants : Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Methodological Issues in Psychopharmacogenetics. In: Pharmacogenetics of Psychotropic Drugs, (ed) Bernard Lerer, Cambridge University Press, New York, 2002
Preskorn SH, Mood Disorders. In: Conn’s Current Therapy 2003 edition, (eds.) Robert E. Rakel, Edward T. Bope, Saunders (Elsevier Science), Philadelphia, 2003

BOOKS:

Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd, Jr. FJ, Principals and Practice of Psychopharmacotherapy 2nd ed.. Williams & Wilkins, Baltimore, 1997
Preskorn SH, Outpatient management of depression: A guide for the primary-care practitioner, 2nd Edition. Caddo, OK: Professional Communications; 1999
Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd,Jr. FJ, Principals and Practice of Psychopharmacotherapy. 3rd ed.. Lippincott Williams & Wilkins, Philadelphia, 2001

LETTERS TO THE EDITOR:

Preskorn SH, Baker B, Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277:1682. Letter
Shad MU, Preskorn SH, A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17:118-119. Letter
Shad MU, Preskorn SH, Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. Journal of Clinical Psychopharmacology 18(4): 346-347, 1998
Shad MU, Preskorn SH, A drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. Journal of Clinical Psychopharmacology 19(5):471-472, 1999
Shad MU, Preskorn SH, Izgur Z, Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. Journal of Clinical Psychiatry 20(3):390-391, 2000
Khan A, Shad MU, Preskorn SH, Lack of sertraline efficacy probably due to an interaction with carbamazepine. Journal of Clinical Psychiatry 61(7):526-527, 2000
Preskorn SH, Greenblatt DJ, Harvey AT, Lack of effect of sertraline on the pharmacokinetics of alprazolam. Journal of Clinical Psychopharmacology 20(5):585-586, 2000
Khan AY, Preskorn, SH, Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. Journal of Clinical Psychiatry 62(5), 375-376

ABSTRACTS:

Harvey AT, Preskorn SH, Mechanism of action of venlafaxine in normal male volunteers (Abstract). Clin Pharmacol Ther 1997;61:175
Preskorn SH, Shad MU, Alderman J, Lane R, Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition. Am Soc Clin Pharmacol Ther. 1998;63:166. Abstract
Preskorn SH, Central adrenergic regulation of cerebromicrocirculation: Relevance to psychiatry. Neuropharmacology in press. (In Press?)
Miceli J, Preskorn SH, Wilner K, Folger C, Tensfeld T, Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clinical Pharmacological Therapeutics 65:171, 1999
Shad MU, Carmichael CA, Preskorn SH, et al, The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clin Pharmacol Ther 1999;65:183 (abstract)
Preskorn, SH, Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. International Journal of Neuropsychopharmacology 3( Suppl 1):5, 2000
Silkey B, Preskorn SH, Golbeck A, Horst W, Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. Poster presentation at Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research," Seattle, Washington, May 11-12, 2000
Silkey B, Preskorn SH, Golbeck A, Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. Poster presentation at 40th Annual NCDEU, Boca Raton, Florida, May 30-June 2, 2000
Reyes LF, Preskorn SH, Khan A, Kumar S, Cullen E, Pratt R, Pharmacokinetics (PK) of donepezil and risperidone in males with schizophrenia. Clinical Pharmacolology and Therapeutics 69:44, 2001
Harvey A, Preskorn SH, The influence of extended-release venlafaxine on QT intervals of normal volunteers. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28-31, 2001
Khan A, Friesen S, Klick-Davis A, Preskorn SH, How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28- 31, 2001
Preskorn SH, Baker B, The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. Poster presentation at AANP 2001
Harvey A, Preskorn SH, The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. Clinical Pharmacology and Therapeutics 71(2), P53, 2002
Silkey B, Preskorn S, Shah R, et al, Multiple medication use and cytochrome P-450-based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. Clin Pharmacol Ther (abstract), in press
Wesnes KA, Preskorn SH, Friesen S, Edgar C, Mikkelson BO, NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer’s disease (AD). Clinical Pharmacology and Therapeutics 71(2), P17, 2002

SPECIAL PRESENTATIONS:

Visiting Professor for Annual Psychopharmacology Day:
- 1997-University of Toronto in Toronto, Ontario, Canada
- 1998-University of Alberta in Edmonton, Alberta, Canada
- 1999-University of Hamilton in Hamilton, Ontario, Canada
Sept. 14, 2002 - German Neuroscience Academy in Versailles, France. "Drug development in psychiatry and the human genome project: Implications for clinical practice."
Oct. 2, 2002 - Keynote address at Annual Psychopharmacology Update Program for the University of Oklahoma at Tulsa. "Drug-drug interactions: Their mechanisms, their clinical presentation, and their clinical relevance."
Oct. 6, 2002 - Keynote address at Annual Psychopharmacology Update Program for the University of Mississippi in Jacksonville, MS. "The rational basis for the combined use of more than one psychiatric medication."